Eurofins Medigenomix to develop and market testing services utilizing SIBA technology
Dec. 17th, 2013
Eurofins Medigenomix, a part of the Eurofins Genomics Business line of Eurofins Scientific and Orion Diagnostica Oy, an in vitro diagnostics company specialising in the development, production and sales of diagnostic test systems, announced that they have signed a co-exclusive technology license agreement. Orion Diagnostic Oy owns the global rights for the SIBA isothermal nucleic acid detection technology in all fields.
“Our general focus is to translate innovative and new technologies into new applications of DNA based analysis. This will allow our Eurofins Genomics business line to generate the high service level we want to provide to our customers”, said Bruno Poddevin, Senior Vice President Eurofins Genomics. “The SIBA technology and the associated expertise of Orion Diagnostica are an excellent fit for Eurofins. The cooperation will allow us to broaden Eurofins’ portfolio with innovative analytical solutions particularly in the area of DNA based authenticity testing for food and related products”, added Peter Persigehl, Managing Director of Eurofins Medigenomix.
“Orion Diagnostica’s new SIBA technology allows a fast, robust, and reliable detection of nucleic acids from a variety of sources and for different identification needs enabling wide range of uses in different fields. We are delighted to enter into this agreement with Eurofins Medigenomix, a leader in the field of Genetic Analyses, and look forward to collaborating on projects such as authenticity testing for clients worldwide,” said Jaakko Rissanen, President, Orion Diagnostica Oy.